Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Kiora Pharmaceuticals ( (KPRX) ) has issued an announcement.
On June 4, 2025, Kiora Pharmaceuticals held its Annual Meeting where stockholders voted on several key proposals. Carmine Stengone and Brian M. Strem, Ph.D. were elected as Class I Directors for a three-year term. Additionally, the compensation of the company’s named executive officers was approved on a non-binding basis, and the appointment of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
The most recent analyst rating on (KPRX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Kiora Pharmaceuticals stock, see the KPRX Stock Forecast page.
Spark’s Take on KPRX Stock
According to Spark, TipRanks’ AI Analyst, KPRX is a Neutral.
Kiora Pharmaceuticals shows strong financial health with solid revenue growth and minimal debt, contributing positively to its stock score. However, weak technical indicators suggest bearish market sentiment, partially offsetting the financial strengths. The attractive valuation with a low P/E ratio presents potential upside, particularly if technical conditions improve.
To see Spark’s full report on KPRX stock, click here.
More about Kiora Pharmaceuticals
Average Trading Volume: 401,073
Technical Sentiment Signal: Sell
Current Market Cap: $8.67M
See more data about KPRX stock on TipRanks’ Stock Analysis page.